Across TCGA pan-cancer cohorts, FCAR Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FCAR data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher FCAR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FCAR expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

THYM, HNSC, and SKCM are the cancer types where FCAR Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	All	0.068	0.977	<.001	24	view →
HNSC	OS	Median	II,III,IV	0.218	0.674	.003	6	view →
SKCM	OS	Median	All	0.726	0.368	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: FCAR tumor-vs-normal RNA expression · all FCAR data types